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Abstract
Background: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and
safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis
plan for the ADAPT as an update to the published protocol and is submitted prior to knowing all outcomes.
Method and design: The ADAPT is a randomised, double-blind, placebo-controlled trial with a primary objective to
determine whether anti-IgE reduces eczema severity as assessed by the validated eczema score (objective SCORAD)
after 24 weeks of treatment in children with severe eczema. This articles outline the overall analysis principles
including considerations on sample definition in each analysis, missing data, and adjusted covariates. Comparability
and representativeness of the randomised groups, primary and sensitivity analyses of the primary and secondary
outcomes as well as subgroup analysis are described.
Results: This prespecified statistical analysis plan has been developed to comply with international guidelines which
will increase the transparency of the data analysis for the ADAPT.
Trial registration: ISRCTN, identifier: ISRCTN15090567. Registered on 3 December 2014;
EU Clinical Trials Register, EudraCT Number: 2010-020841-29. Registered on 14 May 2010. The first participant was
enrolled on 15 January 2015.
Keyword: Statistical analysis plan, Eczema, Paediatric, Atopic dermatitis, Anti-IgE, Omalizumab, Randomised controlled
trial, Xolair
Background
Eczema is a chronic inflammatory skin disorder with a life-
time risk of up to 22% of children by the age of 12–14 years.
The available literature suggests that anti-immunoglobulin E
(anti-IgE) may be of benefit in the treatment of eczema from
at least the age of 7 years [1–4]. Studies and case reports to
date have had small numbers of participants, have not been
randomised or placebo controlled, or have included a
heterogenous mix of participants of different ages.
The Atopic Dermatitis Anti-IgE Paediatric Trial
(ADAPT) is a trial to determine the clinical efficacy and
safety of omalizumab (Xolair, Novartis) for children with
severe atopic eczema. Fuller details on the rationale and
the design for the trial are given in the study protocol
[5]; the prespecified statistical analysis plan (SAP) has
been developed and finalised without knowing the treat-
ment allocation or treatment-related study results.
This paper describes important features of the trial de-
sign and the statistical method and procedures which
need to be adhered to and performed by the statistician
responsible for this study. It should be read in conjunc-
tion with the protocol.
Method and design
The ADAPT is a randomised, double-blind, placebo-
controlled trial of anti-IgE therapy in children with
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severe eczema who have failed topical therapy. In total,
62 children aged 4–19 years are planned to be recruited
within 18 months. Participants are eligible if they have
severe eczema defined as an objective SCORing Atopic
Dermatitis (SCORAD) score of over 40 at assessment
(detailed exclusion and inclusion criteria are in the pub-
lished protocol). Participants will be individually rando-
mised in a 1:1 ratio to two treatment arms (omalizumab
and matched placebo) using minimisation to ensure the
balance of total IgE (≤1500 and >1500) and age (<12 and
≥12 years). The allocation will be performed by an on-
line randomisation system hosted at the King’s Clinical
Trials Unit (CTU).
Primary objective
The primary objective of this study is to assess whether
omalizumab will reduce eczema severity as assessed by
the validated eczema score (SCORAD) after 24 weeks of
treatment in children with severe eczema.
Secondary objectives
The study will examine the influence of the study inter-
vention on the rate of treatment failure, rate of alterna-
tive systemic therapy, quality of life, eczema severity as
assessed by the Eczema Area and Severity Index (EASI),
effect on co-existing allergic disease, number of eczema
exacerbations, infective episodes of eczema, change in
reactivity to food and aeroallergens and change in
allergen-specific IgE. Detailed descriptions of the pri-
mary and secondary outcomes can be found in Table 1
as well as in the study protocol [5].
Sample size
Omalizumab is administered via subcutaneous injec-
tions which require fortnightly or monthly attendance
at clinic to receive them. It is available from the man-
ufacturers at an undisclosed cost in the United King-
dom. In order for omalizumab to be adopted into
practice, a treatment effect that would make an im-
portant impact on the children’s quality of life would
be required. Through discussion and consultation
with the funder and clinicians, a relative reduction of
around 33% in symptoms was selected to be the
minimum important treatment effect to detect. Given
the inclusion criteria the mean baseline SCORAD
score is anticipated to be 45 and we aim to detect a
change in SCORAD score of 13.5 points between the
treatment arms. Based upon a study by Hindley [6]
we assume that the standard deviation (SD) is 15,
using a significance level of 5% with 90% power, and
including a 15% dropout rate we aim to recruit 62
participants (31 each to each arm).
Minimum Clinically Important Difference (MCID)
The study was powered to detect a minimum important
treatment effect of a 13.5-point absolute change in ob-
jective SCORAD score taking into account the patient
burden and high treatment cost. The MCID is the smal-
lest difference in an outcome measure that represents a
clinically relevant outcome to the patient, regardless of
cost and burden. There is no verified MCID for
SCORAD score in this severely affected paediatric popu-
lation. In order to determine MCID, published studies
have recommended the use of both anchor- and
distribution-based methods [7]. A study by Schram et al.
[8], which adopts an anchor-based approach, suggests
that a MCID for the objective SCORAD score is 8.2.
However, this is based on data from three RCTs on
treatments for atopic eczema which included adults. The
MCID reported by Schram et al. for children only, based
on a subsample of n = 25, with an average age of
9.4 years, is 9.0. Since the patients included in the study
by Schram et al. also had a milder baseline severity we
employed a distribution-based method using data col-
lected from the trial to calculate a MCID. Using the data
from the first 47 ADAPT patients who completed week-
24 assessments (75% of total sample size) adopting 0.7
SD of the change in score from baseline gives a MCID
of 8.5. These MCIDs will be used to guide interpretation
of the results from the primary analysis.
General statistical principles
The principle of intention-to-treat (ITT) will be the
main strategy of the analysis adopted for the primary
outcome and all secondary outcomes. That is, all ran-
domised participants will be analysed in the group ran-
domised regardless of whether the allocated study
treatments were received, or whether other interventions
were received and regardless of any protocol deviations or
violations [9]. A safety set (SS) population will consist of
participants who receive at least one dose of allocated
treatment, regardless of their eligibility for the study. The
harm analyses will compare the harm outcomes between
the two treatment groups in the safety population.
All regression analyses will include the minimisation
variables (IgE (≤1500, >1500) and age (<10 or ≥10 years)
as covariates. This is because adjustment for these strati-
fication factors in the randomisation process will main-
tain correct type I error rates [10]. Additionally, for
continuous outcomes, the outcomes measured at base-
line will be included in regression analysis to increase
power [11].
Any examination of subgroups, not specifically identi-
fied in the SAP, will be considered exploratory in nature
and will be clearly identified. All p values will be two-
sided and the significance level is set at 5% unless other-
wise stated.
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Missing data
The number and proportion of participants missing ob-
jective SCORAD values by visit number will be tabu-
lated. The primary analysis includes all observed data
and assumes the probability that missing data is not
dependent on the values of the unobserved data itself,
conditional on the observed values of the variables in-
cluded in the analysis model (missing at random (MAR)
assumption). Sensitivity analysis will explore departures
from the main MAR analysis assumption for all patients
on the primary outcome using a pattern-mixture mul-
tiple imputation (MI) approach [12].
Imputation under MAR will initially be performed
separately within each arm following the guidance sug-
gested by White et al. [13]. The variables in the imput-
ation model will be the same as those in the analysis
Table 1 Outcomes and analysis models
Outcome Endpoints Category Analysis model
Primary
Objective SCORAD Difference in the objective SCORAD in both
groups after 24 weeks of treatment
Continuous outcome
measures
Mixed-effects linear regressions
(primary)
Instrumental variable regression
Secondary
Treatment failure Participants who have persistent severe
eczema despite 2 courses of rescue therapy
(0.5 to 1 mg/kg/day of orally administered
prednisolone for a week at a maximum dose
of 40 mg/day, followed by a week at 50% of
this dose)
Binary outcome
measures
Logistic regression model
Alternative systemic therapy Requirement for alternative systemic therapy Binary outcome
measures
Logistic regression model
Eczema quality of life • POEM
• (C)DLQI
Continuous outcome
measures
ANCOVA
Eczema severity • Subjective SCORAD
• EASI score
Continuous outcome
measures
ANCOVA
Effect on co-existing allergic
disease
PADQLQ Continuous outcome
measures
ANCOVA
Number of eczema exacerbationsc • Clinician-diagnosed exacerbation of eczema
or
• Increase on SCORAD by 15 points from last
recorded SCORAD with participant/parent
perception of worsening eczema
Numerical outcome
measures
Poisson regression
Negative binomial regression
model
Zero-inflated Poisson regression
model (as appropriate)
Infective episodes of eczemac Clinician-diagnosed and -treated infective
episode of eczema, or clinically apparent,
culture-positive infective exacerbations
Numerical outcome
measures
Poisson regression
Negative binomial regression
model
Zero-inflated Poisson regression
model(as appropriate)
Allergen-specific IgEa Change in allergen-specific IgE Continuous outcome
measures
ANCOVA
Reactivity to food and aeroallergensa Change in skin-prick test reactivity to food
and aeroallergens
Numerical outcome
measures
Poisson regression
Negative binomial regression
model
Zero-inflated Poisson regression
model
Safety
Adverse eventsb Spontaneously reported AE will be collected
throughout the follow-up period
Binary outcome Descriptive analysis
Urea and electrolytes, creatinine,
FBC, eosinophils, LFT, IgE, vitamin D,
iron level, bone profile
Surveillance tests where abnormal ranges are
defined using the ranges specified by the
processing laboratory
Binary outcome Descriptive analysis
aOnly collected at screening and 24 weeks of treatment. The remaining outcomes are collected at baseline, 4-weekly during the 24 weeks of treatment, 36 weeks
and 48 weeks
bBlood test and urine samples will be collected at baseline, 24 weeks, 36 weeks and 48 weeks. Clinical observations will be examined at every visit
cChi‐square goodness‐of‐fit tests will be used to select the suitable model
ANCOVA analysis of covariance, IgE immunoglobulin E, SCORAD SCORing Atopic Dermatitis, PADQLQ Paediatric Allergic Disease Quality of Life Questionnaire,
(C)DLQI (Children’s) Dermatology Life Quality Index, EASI Eczema Area and Severity Index, AE adverse events, POEM Patient-oriented Eczema Measure, FBC full
blood count, LFT liver function test
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model without including more auxiliary variables (e.g.
predictors of missingness) after taking into account the
relatively small sample size of this study [14]. Imputa-
tions will then be modified to reflect departures from
the MAR assumption.
We will investigate the impact of a better or poorer re-
sponse than that predicted by MAR (lower/higher ob-
jective SCORAD scores) for patients with missing data.
Specifically, we define δ as the postulated mean differ-
ence in the rate of change of the objective SCORAD
score between the observed and unobserved cases over
24 weeks, conditional on the variables in the imputation
model. For each patient we then modify the MAR im-
puted observations accordingly by δ. Imputed data sets
will be analysed using the primary analysis model. Re-
sults will be combined across imputed data sets using
Rubin’s rules. We will repeat the analysis for a range of
δs corresponding to ±10, 20, 30, 40 and 50% of the rate
of change of the objective SCORAD score observed over
24 weeks in all patients. We will also consider the possi-
bility that data is missing informatively in one arm only
and employ the outlined imputation approach separately
by trial arm.
For baseline covariates, the amount of missing data is
expected to be small. However, if this happens, in case
of loss of power using observed data, mean values will
be calculated from the non-missing values for the base-
line variable using pooled data from both treatment
groups [15]. With reference to those categorical vari-
ables, the imputed mean will be rounded up to nearest
category level. This is justifiable because randomisation
ensures that baseline scores are independent of treat-
ment group and imputation keeps the statistical effi-
ciency in the estimation of the treatment effect.
For those missing items within questionnaires, we
firstly use the missing value guidance provided for
questionnaires. If no guidance is provided we will then
impute the missing values using the mean of the ob-
served items within the same subscale if 20% or fewer
items are missing. The scale score will be calculated
based on the complete values and these replacements
[16]. If more than 20% of items are missing in the ques-
tionnaire, multiple imputation will be used as discussed
above.
Statistical analysis
Trial profile
A Consolidated Standards of Reporting Trials (CON-
SORT) flow chart will be constructed (see Fig. 1). This
will include the number of eligible patients, the number
of patients agreeing to enter the trial, the number of par-
ticipants withdrawing and lost to follow-up, the number
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) trial flow chart for the Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT)
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continuing through the trial, and the number included
in the analyses.
Comparability/representativeness of randomised groups
All baseline descriptive variables of participants will be
summarised by treatment arm. Continuous data will be
expressed as N/mean/SD/min/Q1 (lower quartile)/me-
dian/Q3 (upper quartile)/max. Tabulations of frequen-
cies for categorical data will include all possible
categories and will display the number of observations
in a category as well as the percentage (%) relative to
number of available values within the respective treat-
ment group unless otherwise specified. The number of
missing values is reported for both types of variables.
This will allow a visual assessment of whether the ran-
domisation procedure succeeded in producing compar-
able arms, and tests of statistical significance will not be
undertaken between arms at baseline; rather the clinical
importance of any imbalance will be noted.
The number of participants who receive the injection
outside the planned visit window of 5 days or more will
be reported by visit number and treatment arm. Also,
the mean cumulative dosage by planned dose will be
plotted by treatment arm and separately for those receiv-
ing monthly and fortnightly injections.
Descriptive statistics for outcomes
The distributions of all efficacy outcomes (in Table 1)
will be presented in histograms (continuous/count) or
bar charts (ordinal/binary) both overall and by group at
each assessment point. A single table will be outputted
with summary statistics for all outcomes by group and
visit point. Furthermore, summary statistics will be plot-
ted by line graphs for each outcome across time by
intervention. Only participants with a completely re-
corded outcome will be used to calculate the summary
measures.
Analysis of primary efficacy outcome
Primary analysis
A linear mixed model will be used to obtain an estimate
for the mean difference in objective SCORAD scores be-
tween the two treatment groups. Participant will be in-
cluded as a random intercept (investigating adding a
random slope on time), and time (investigating the pos-
sibility of linearising this effect across 8, 12, 16, 20 and
24 weeks), time-by-group interaction, baseline objective
SCORAD score, IgE (≤1500, >1500) and age (<10 or
≥10 years) as fixed effect. An overall treatment effect for
objective SCORAD score at 24 weeks will be estimated.
The response yij is the objective SCORAD score meas-
urement for patient i at time tj. Both random intercept
model (a) and random intercept and slope model (b) will
be fitted as specified below:
(a) Y ij ¼ β0 þ β1TRTi þ β2SCORAD0i þ β3IgEi þ β4Agei
þβ5t12 þ β6t16 þ β7t20 þ β8t24 þ β9t12
TRTi þ β10t16  TRTi þ β11t20  TRTi
þβ12t24  TRTi þ bi þ eij
(b) Y ij ¼ β0 þ β1TRTi þ β2SCORAD0i þ β3IgEi þ β4Agei
þβ5t12 þ β6t16 þ β7t20 þ β8t24 þ β9t12
TRTi þ β10t16  TRTi þ β11t20  TRTi
þβ12t24  TRTi þ b1i þ b2itj þ eij;
where j = time points (8, 12, 16, 20 and 24 weeks), i =
participants,
TRTi: dummy variable (TRTi = 0 or 1) of patient i,
IgEi: dummy variable for IgE (=0 or 1) of patient i,
SCORADi
0: baseline SCORAD score of patient i,
Agei: dummy variable for age (<10 or ≥10 years) of
patient i,
txx: dummy variable for time (= 0 or 1) at time point
xx weeks.
Where bi and b1i are random intercepts, b2i is random
slopes, both eij and b1i, following normal distributions.
An unstructured covariance matrix will be used. Models
will be fitted using residual maximum likelihood
(REML). The estimated treatment effect at 24 weeks, β1
+ β12, will be reported with 95% confidence intervals and
corresponding p value.
Model (a) will be the primary analysis model unless
there is strong evidence for mis-specification of the
model. The random slope model is less restrictive and
possibly more realistic in its assumptions, i.e. the object-
ive SCORAD score trajectories for each individual start-
ing from a different level and following a different trend
with a different slope. The primary interest is in deter-
mining whether β1 + β12 is significant and whether this
varies between the two models (a and b).
The conclusion of the trial will be based on this
analyses.
Planned sensitivity analyses
To investigate the robustness of the results of the pri-
mary analysis we will undertake a number of sensitivity
analysis:
1. Subsequent adjustment for cumulative use of potent
topical steroids (continuous variable) at 24 weeks,
alternative systemic therapy (yes/no) at 24 weeks,
rescue medication (yes/no) at 24 weeks based on the
primary model
2. An analysis of Complier Average Causal Effect
(CACE) by a two-stage least squares instrumental
variable regression would be performed for the
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primary endpoint as analysis based upon ITT may
underestimated the effect of actually receiving the
treatment [17]. Here, we defined ‘compliers’ as those
who complete more than 50% of injections (that is
injections received relative to injections planned for
the 24-week study period in groups). Randomisation
will be used as an instrumental variable for treatment
received with the same covariates in primary analysis
models.
Analysis of secondary efficacy outcomes
All analyses for secondary efficacy outcomes will be
based on the ITT population and defined at week 24 un-
less specified otherwise. The missing data will be tackled
according to the strategies mentioned above.
For each secondary outcome, we will adjust for the
minimisation variables IgE (≤1500, >1500), age (<10 or
≥10 years) and baseline data (as appropriate).
Treatment failure (binary) and alternative systemic
therapy (binary) will be analysed using a logistic regres-
sion model. The estimated treatment effect (odds ratio)
will be reported with 95% confidence intervals and cor-
responding p value. Subjective SCORAD, EASI, Patient-
Oriented Eczema Measure (POEM), Paediatric Allergic
Disease Quality of Life Questionnaire (PADQLQ), (Chil-
dren’s) Dermatology Life Quality Index ((C)DLQI) scores
and allergen IgE levels will be analysis using analysis of
covariance (ANCOVA). The estimated treatment effect
(mean difference) will be reported with 95% confidence
intervals and corresponding p value. The number of
skin-prick test reactivities, infective episodes of eczema
count, and number of eczema exacerbations will be ana-
lysed by Poisson regression, Negative binomial regres-
sion or zero-inflated Poisson regression models after
checking the distribution of the dependent variable by
Pearson chi‐square goodness‐of‐fit tests will ensure the
selection of the correct statistical model. The estimated
treatment effect (odds ratio) will be reported with 95%
confidence intervals and corresponding p value. A sum-
mary of models for each of the outcomes can be found
in Table 1.
Analysis of safety outcomes
Information on adverse events (AE) will be collected by
means of spontaneous reports from patients and carers,
clinical observation and clinical examinations and blood
tests. Adverse events will be coded using terms chosen
by the clinical investigators with reference to the Med-
ical Dictionary for Regulatory Activities (MedDRA) at
the Preferred Term level. Abnormal ranges for blood
tests will be defined using the ranges specified by the la-
boratory processing the sample.
Adverse events will be tabulated overall by severity
and type (AE, adverse reaction, unexpected adverse
reaction, serious AE, serious adverse reaction or unex-
pected serious adverse reactions). These will be sum-
marised over the 48-week follow-up period and, where
appropriate, by time of occurrence.. The numerator will
indicate the number of affected participants at each time
point from the SS population. The denominators will
show how many participants were in the trial at the cor-
responding time point. If appropriate, the difference in
proportion (95% confidence interval) will be estimated
and time-to-event curves by treatment arm will be plot-
ted. All AE will be listed individually.
Subgroup analyses
A subgroup analysis is planned to investigate whether
intervention effects differ between adherence, defined as
the injections received relative to the injections planned for
the 24-week study period in groups (≤50%, >50%; ≤75%,
>75%; ≤90%, >90%). All subgroup analyses will be analysed
using the same method as for the primary outcome. The
results will be displayed by means of a forest plot.
Software
Data management: an online data collection system for
clinical trials (MACRO; InferMed Ltd.) will be used.
This is hosted on a dedicated server at Kings’ Clinical
Trial Unit. The CTU data manager will extract data
periodically as needed and provide these in comma sepa-
rated (.csv) format.
Statistical analysis: analysis will be performed using
statistical software Stata, R or SAS.
Tables and figures
The SAP describes the conventions to be used for pre-
senting results in text and in tables and figures. Those
conventions are based on the International Conference
on Harmonisation (ICH) guideline for reporting clinical
trial results. The planned tables are:
 Analysis population by study centre and treatment
group
 Withdrawals, protocol deviations and violations by
treatment group
 Baseline demographic and clinical characteristics by
treatment group
 Baseline blood/urine investigations by treatment
group
 Descriptive analysis for primary efficacy outcomes
by treatment group across study visits
 Inferential analysis for primary efficacy outcomes by
treatment group
 Sensitivity analysis for primary efficacy outcomes by
treatment group
 Secondary efficacy outcomes by treatment group
 AE by treatment group across study visits
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The planned figures are:
 Flow chart of participants through the study
 Bar chart/histogram for efficacy outcome over time
by overall and treatment group
 Linear graph for efficacy outcome over time by
treatment group
 Forest plot of effect of treatment on primary for all
participants and for prespecified subgroups
This article presents the SAP for the ADAPT and
should be read in conjunction with the trial protocol [5].
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